The efficacy and response of donepezil in severe Alzheimer disease: multi-modal neuroimaging analysis (structural and functional neuroimaging) of open-label, clinical trial
Not Applicable
- Conditions
- Alzheimer disease
- Registration Number
- JPRN-UMIN000009473
- Lead Sponsor
- Department of Neuropsychiatry, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
either previous history or now taking other choline inhibitors (galantamine, rivastigmine) and memantine, taking antipsychotic or antidepressant medication ,there was a previous history of mental illness or substance abuse, either an MRI or a CT scan had revealed focal brain lesions,routine blood tests (including evaluation of serum vitamin B12 and thyroid function) were abnormal findings, the patient has pacemaker, other findings in terms with the aims of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method multi-modal neuroimaging analysis 1 Structural neuroimaging analysis Brain MRI: voxel-based morphometry (VBM) diffusion tensor imaging (DTI) 2 Functional neuroimaging analysis single photon emission computed tomography (SPECT) near-infrared spectroscopy (NIRS)
- Secondary Outcome Measures
Name Time Method 1 Cognitive assessment Mini-Mental State Examination (MMSE) Clock drawing test The Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog) Frontal assessment battery (FAB) 2 Behavior assessment Clinical assessment for spontaneity (CAS) Neuropsychiatry Inventory Questionnaire (NPI-Q) Quality of life-Alzheimer Disease (QOL-AD) Scale